Quotient Clinical Acquires Co-Formulate Limited
PTSM: Pharmaceutical Technology Sourcing and Management
Quotient Clinical announced on Dec. 16, 2015 that is has acquired Co-Formulate Limited.
On Dec. 16, 2015 Quotient Clinical announced that it has acquired contract development company Co-Formulate Limited.
Quotient Clinical is a drug-development services company. The company created a Translational Pharmaceutics platform, which integrates formulation development, GMP manufacturing, and clinical testing. Co-Formulate Limited is a contract product development company that provides a range of comprehensive development, analytical, and regulatory services.
Quotient Clinical’s acquisition of Co-Formulate extends Quotient’s existing pharmaceutical development capabilities across solid, semisolid and liquid formulations. Co-Formulate is based adjacent to Quotient’s new GMP facility in Nottingham, UK, which will enable integration of formulation development and GMP manufacturing services.
Financial terms of the transaction were not disclosed.
Source: Quotient Clinical
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.
